Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.
Request Insights
IN THE NEWSSeptember 2nd, 2020: BiomX Inc. announced that it has entered into a collaboration with Boehringer Ingelheim for the discovery of microbiome-based biomarkers for inflammatory bowel disease (IBD).
December 19th, 2017: DuPont Nutrition & Health, the subsidiary of DuPont de Nemours, Inc., announced that it has partnered with APC Microbiome Institute for the creation of a Microbiome Venture so as to advance in the field of new microbiome science-based solutions.
The global human microbiome market is estimated to garner a revenue of USD 3251.4 Million by the end of 2031 by growing at a CAGR of 22.3% over the forecast period, i.e., 2022 – 2031. Moreover, in the year 2021, the market generated a revenue of USD 438.3 Million. The growth of the market can be attributed to the increasing research and developments in the field of microbiology and the growing advancements in the field of human microbiome project (HMP). The first phase of the human microbiome project (HMP) research initiative was launched in the year 2007 by the National Institutes of Health (NIH) of the United States so as to improve the understanding of the microbiota involved in human health and disease. Later, in the year 2014, the second phase of the study, which was known as the Integrative Human Microbiome Project (iHMP), was launched with the aim of generating resources to characterize the microbiome. The current understanding of the human microbiome includes 18 studies with 31596 samples and 161265 files advanced search queries according to the statistics by the NIH Human Microbiome Project (HMP) Data Portal. The statistics further stated that 633 samples from buccal mucosa for the study of HMP, 2151 samples from stool, and 13314 samples for FASTQ data from female subjects were collected for the study. Additionally, the growing prevalence of lifestyle-related diseases is also projected to drive the market growth in the coming years.
Get more information on this report: Request Sample PDF
Regionally, the global human microbiome market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is projected to garner the largest revenue of USD 1859.8 Million by the end of 2031, up from a revenue of USD 251.6 Million in the year 2021. The growth of the market in the region can primarily be attributed to the growing expenditure on research and developments (R&D) in the region, presence of a strong healthcare network, along with the surge in initiatives of the governments of the region for promoting research on human health. Besides this, the surge in health expenditure is also expected to add to the market growth in the region during the forecast period. According to the statistics by the World Bank, the current health expenditure as a share of GDP in North America grew from 12.197% in the year 2000 to 16.322% in the year 2019. On the other hand, the market in Europe is projected to register the second-largest revenue of USD 702.3 Million by the end of 2031, up from a revenue of USD 92.9 Million in the year 2021. The market in the region is further segmented by country into Germany, United Kingdom, France, Italy, Spain, Russia, and the Rest of Europe. The market in Germany is projected to garner the largest revenue of USD 169.3 Million by the end of 2031, up from a revenue of USD 21.6 Million in the year 2021.
The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
The global human microbiome market is segmented by product into probiotics, prebiotics, diagnostic tests, drugs, and others. Out of these, the probiotics segment is anticipated to garner the largest revenue of USD 1427.7 Million by the end of 2031, up from a revenue of USD 187.2 Million in the year 2021. By disease type, the market is segmented into infectious disease, obesity, diabetes, gastrointestinal diseases, cancer, cardiovascular diseases, and others. Out of these, the gastrointestinal diseases segment is projected to garner the largest revenue of USD 976.2 Million by the end of 2031, up from a revenue of USD 128.2 Million in the year 2021. By organism type, the market is segmented into aerobic organisms, obligative & facultative anaerobes, genetically engineered strains, BSL-2 & spore-forming species, and others. Out of these, the obligate & facultative anaerobes segment is projected to garner the largest revenue of USD 1233.3 Million by the end of 2031, up from a revenue of USD 168.0 Million in the year 2021. By application, the market is segmented into therapeutics and diagnostics, out of which, the therapeutics segment is projected to grow with the highest CAGR of 23.5% during the forecast period. By technology, the market is segmented into genomics, proteomics, and metabolomics. Out of these, the genomics segment is projected to garner the largest revenue of USD 1916.9 Million in the year 2021
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global human microbiome market that are included in our report are Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, SECOND GENOME, Synthetic Biologics, Inc., YSOPIA Bioscience, 4D pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc., and others.
FREQUENTLY ASKED QUESTIONS
The increasing focus on the development of human microbiome therapeutics, and the rising prevalence of lifestyle-related diseases are some of the major factors projected to drive the market growth.
The market is anticipated to attain a CAGR of 22.3% over the forecast period, i.e., 2022 – 2031.
The stringent government regulations is one of the major factors estimated to hamper the market growth.
The market in North America is projected to garner the largest revenue of USD 1859.8 Million by the end of 2031 and provide more business opportunities.
The major players in the market are Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, SECOND GENOME, Synthetic Biologics, Inc., YSOPIA Bioscience, 4D pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, disease type, organism type, application, technology, and by region.
The probiotics segment is anticipated to garner the largest revenue of USD 1427.7 Million by the end of 2031 and display significant growth opportunities.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
